Existing asthma treatments are associated with side effects and limitations, which has led to an interest in alternative and complementary therapies. Given the anti-inflammatory properties of pomegranate, the present study aimed to determine the impact of pomegranate extract supplementation on lung function parameters evaluated through spirometry, high-sensitivity C-reactive protein (hs-CRP), pro-oxidant antioxidant balance, and interleukin 35) (IL-35) in participants with mild and moderate allergic asthma (based on forced expiratory volume in 1 second (FEV1) and clinical symptoms). Participants with mild and moderate allergic asthma (n = 64) were randomly assigned to two groups: the intervention group, which received two pomegranate extract capsules (500 mg/day), or the control group for eight weeks. Also, the physician prescribed similar drugs to the participants in the study. Independent samples T-test and Mann–Whitney U were used to compare the quantitative outcomes between the intervention group and the comparison group. The Wilcoxon test and the paired T-test were applied for within-group comparisons. A p-value <0.05 was considered significant. At the end of the study, the change levels of IL-35 in the intervention group increased significantly compared to the control group. In terms of the lung function parameters, FEV1/ forced vital capacity (FVC) (FEV1/FVC) ratio enhanced significantly in the intervention group compared to the control group. Also, the pomegranate extract significantly improved forced expiratory flow 25–75% (FEF25−75%), FEV1/FVC ratio, and FEV1 in the intervention group. No significant changes in FEV1 values were observed between the two groups at the end of the study. Also, no significant changes were seen in other indicators. It seems that pomegranate extract can improve lung function parameters and IL-35 expression in mild and moderate allergic asthma.Clinical trial registrationhttps://www.irct.ir/trial/45612; identifier: IRCT20200205046384N1.
Background: Asthma essentially represents a chronic inflammatory disease that manifests as a lifelong condition with different severity throughout the life of patients with asthma. Pomegranate holds three times the antioxidant activity compared to other polyphenol-rich food sources like green tea, which may positively impact asthma.Aim of the study: This research aimed to investigate the pomegranate supplementation influences clinical symptoms, eosinophil, basophil, and neutrophil counts in patients with allergic asthma.Materials and Methods: Participants (n = 64) suffering from mild to moderate allergic asthma were randomly divided into two groups: The control group received placebo capsules and the intervention group received 250 mg pomegranate extract capsules twice a day (for 8 weeks). To analyze the data, we used SPSS software (version 22). The significance level of p-value was considered less than 0.05.Results: The findings showed that the pomegranate extract improved patients’ clinical symptoms like daily breath shortness, nocturnal breath shortness, and limitation of asthma-related activity in the intervention group compared to the control group. Furthermore, eosinophil, basophil, and neutrophil counts were significantly decreased in the intervention group. Also, by comparing the two groups, the levels of change in neutrophils and eosinophils were statistically significant.Conclusion: It appears that the pomegranate extract can ameliorate some clinical symptoms and reduce neutrophils, basophils, and eosinophils in allergic asthma patients.Clinical Trial Registration:https://www.irct.ir/trial/45612; identifier: IRCT20200205046384N1.
Asthma is commonly associated with chronic airway inflammation and is the underlying cause of over a million deaths each year. <i>Crocus sativus L</i>, commonly known as saffron, when used in the form of traditional medicines, has demonstrated anti-inflammatory effects which may be beneficial to individuals with asthma. The objective of this study was to develop a clinical prediction system using an artificial neural network to detect the effects of <i>C sativus L</i> supplements on patients with allergic asthma. A genetic algorithm–modified neural network predictor system was developed to detect the level of effectiveness of <i>C sativus L</i> using features extracted from the clinical, immunologic, hematologic, and demographic information of patients with asthma. The study included data from men (n=40) and women (n=40) individuals with mild or moderate allergic asthma from 18 to 65 years of age. The aim of the model was to estimate and predict the level of effect of <i>C sativus L</i> supplements on each asthma risk factor and to predict the level of alleviation in patients with asthma. A genetic algorithm was used to extract input features for the clinical prediction system to improve its predictive performance. Moreover, an optimization model was developed for the artificial neural network component that classifies the patients with asthma using <i>C sativus L</i> supplement therapy. The best overall performance of the clinical prediction system was an accuracy greater than 99% for training and testing data. The genetic algorithm–modified neural network predicted the level of effect with high accuracy for anti–heat shock protein (anti-HSP), high sensitivity C-reactive protein (hs-CRP), forced expiratory volume in the first second of expiration (FEV<sub>1</sub>), forced vital capacity (FVC), the ratio of FEV<sub>1</sub>/FVC, and forced expiratory flow (FEF<sub>25%-75%</sub>) for testing data (anti-HSP: 96.5%; hs-CRP: 98.9%; FEV<sub>1</sub>: 98.1%; FVC: 97.5%; FEV<sub>1</sub>/FVC ratio: 97%; and FEF<sub>25%-75%</sub>: 96.7%, respectively). The clinical prediction system developed in this study was effective in predicting the effect of <i>C sativus L</i> supplements on patients with allergic asthma. This clinical prediction system may help clinicians to identify early on which clinical factors in asthma will improve over the course of treatment and, in doing so, help clinicians to develop effective treatment plans for patients with asthma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.